<DOC>
	<DOCNO>NCT00031564</DOCNO>
	<brief_summary>RATIONALE : Vaccines make insert laboratory-treated gene person 's tumor cell may make body build immune response kill tumor cell . Interleukin-2 may stimulate person 's white blood cell kill cancer cell . Combining vaccine therapy interleukin-2 may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine vaccine therapy interleukin-2 treating patient stage IV kidney cancer .</brief_summary>
	<brief_title>Phase II Study B7-1 Gene-Modified Autologous Tumor Cell Vaccine Systemic IL-2</brief_title>
	<detailed_description>OBJECTIVES : - Determine percentage patient stage IV renal cell carcinoma reduction tumor size treatment B7-1 gene-modified autologous tumor cell vaccine interleukin-2 . - Determine immunogenicity regimen patient . - Determine overall survival patient treat regimen . - Determine local systemic toxicity regimen patient . OUTLINE : Tumor tissue vaccine preparation obtain patient undergo palliative surgical resection primary tumor therapeutic resection metastasis . At approximately 3-6 week surgery , patient receive B7-1 gene-modified autologous tumor cell vaccine subcutaneously ( SC ) day 1 , 29 , 57 . At 6 week first vaccination , patient receive interleukin-2 ( IL-2 ) SC five day week 6 week ( day 43-82 ) . Patients stable respond disease day 106 may receive additional vaccination absence disease progression unacceptable toxicity . Patients follow 3 week last dose IL-2 . PROJECTED ACCRUAL : Approximately 30 patient accrue study .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage IV renal cell carcinoma Symptomatic primary tumor resectable metastasis Measurable disease post resection No symptomatic brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : Eastern Cooperative Oncology Group ( ECOG ) 01 Life expectancy : Not specify Hematopoietic : WBC great 4,000/mm^3 Platelet count great 100,000/mm^3 Hemoglobin great 10 g/dL Hematocrit great 30 % Hepatic : Bilirubin le 2 time normal SGOT le 3 time normal Renal : Creatinine le 1.5 mg/dL OR Creatinine clearance great 60 mL/min Cardiovascular : No evidence active myocardial ischemia , prior myocardial infarction , arrhythmia Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No contraindication surgical resection No history immunodeficiency disease No known allergy penicillin PRIOR CONCURRENT THERAPY : Biologic therapy : Prior interleukin2 , interferon alfa , biologic agent allow Chemotherapy : Not specify Endocrine therapy : No concurrent corticosteroid ( except replacement dos adrenal insufficiency ) Radiotherapy : Not specify Surgery : See Disease Characteristics Other : No concurrent immunosuppressant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>stage IV</keyword>
	<keyword>renal cell carcinoma</keyword>
</DOC>